CRC is a molecularly heterogeneous disease, involving a number of genes that contribute to the transformation from benign neoplasia to invasive carcinoma, and ultimately to metastatic CRC.3 Among these genes, the Kirsten rat sarcoma viral oncogene homologue (KRAS), a GTPase and member of RAS family, plays a pivotal role in oncogenesis, driving tumour development in ~50% of CRC patients.4KRAS mutations occur relatively early in tumourigenesis and contribute to the progression from adenoma to carcinoma. The gene discussed is KRAS; the disease is neoplasm.